Transaction DateRecipientSharesTypePriceValue
20th August 2020Simon N. Pimstone45,000Other acquisition or disposition$0.00
1st July 2020Michael R Hayden1,778Exercise of derivative$0.00
9th June 2020Michael M Tarnow5,144Exercise of derivative$3.52$18,106.88
1st June 2020Sherrington Robin1,630Payment by withholding$13.70$22,331.00
1st June 2020Sherrington Robin8,230Exercise of derivative$3.56$29,298.80
1st June 2020Simon N. Pimstone3,000Open or private sale$14.43$43,290.00
29th May 2020Simon N. Pimstone5,000Open or private sale$13.99$69,950.00
29th May 2020Frank A Holler3,086Exercise of derivative$3.56$10,986.16
26th May 2020Simon N. Pimstone6,172Exercise of derivative$3.56$21,972.32
26th May 2020Simon N. Pimstone1,108Payment by withholding$14.90$16,509.20
Xenon Pharmaceuticals
Xenon Pharmaceuticals logo

Xenon Pharmaceuticals, Inc. focuses on the treatment of epilepsy. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Ticker: XENE
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1582313
Employees: 104
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $44 M (78%)
Marketable Securities, Current: $159 M (35%)
Assets, Current: $207 M (42%)
Property, Plant and Equipment, Net: $2 M (41%)
Assets: $211 M (42%)
Liabilities, Current: $21 M (-51%)
Liabilities: $21 M (-61%)
Common Stock, Value, Issued: $398 M (35%)
Common Stock, Shares, Issued: $35 M (24%)
Additional Paid in Capital, Common Stock: $42 M (3%)
Retained Earnings (Accumulated Deficit): $257 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $990 Th (0%)
Stockholders' Equity (Parent): $189 M (0%)
Liabilities and Equity: $211 M (42%)
Research and Development: $11 M (-52%)
General and Administrative Expenses: $3 M (-50%)
Operating Income/Loss: $646 Th (-92%)
Provision for income taxes: $39 Th (-2%)
EPS (basic): $0 (-100%)
EPS (diluted): $0 (-100%)